Search

Researchers have submitted a patent application for methods to diagnose and treat ischemic eye disease, specifically focusing on proliferative diabetic retinopathy (PDR). The application includes a range of biomarkers that can be used for diagnosis, prognosis, and monitoring treatment of PDR. The methods involve obtaining vitreous samples from patients and measuring the expression levels of specific biomarkers to diagnose and treat PDR effectively. The patent application aims to provide innovative approaches to address the challenges associated with diabetic retinopathy, a leading cause of vision loss in adults. [Extracted from the article]

The article discusses autoimmune pancreatitis (AIP) and its association with IgG4-related disease (IgG4-RD), characterized by inflammation of the pancreas due to hypersensitivity to the body's own proteins. Researchers from Kindai University and the National Institute of Health conducted a study on murine models of AIP/IgG4-RD, revealing the role of plasmacytoid dendritic cells (pDCs) producing IFN-a and IL-33 in the development of AIP. The study also highlighted the involvement of TLR3 signaling, chemokine interactions, and immune system elements like IFN-a, IL-33, CXCL9, and CXCL10 as potential biomarkers for diagnosis and monitoring of AIP/IgG4-RD in both murine models and human patients. [Extracted from the article]

A recent report from researchers at University Hospital Basel in Switzerland discusses the association between acute kidney injury (AKI) and the activation of endothelial cells (EC) during coronary angiography. The study analyzed the effect of recombinant human C1 inhibitor (rhC1INH) on AKI and EC activation markers. The results showed that CM administration during coronary angiography only mildly activated ECs within the first 48 hours, which did not explain subsequent AKI. Additionally, the administration of rhC1INH did not reduce EC activation or CC-chemokine ligand-5 (CCL5) levels. This research provides insights into the relationship between AKI and EC activation during coronary angiography. [Extracted from the article]

A study conducted by researchers at the First Hospital of China Medical University has analyzed the potential biological significance of CCL5 in pan-cancer prognosis and immunotherapy. The study found that CCL5 plays a crucial role in the advancement of human cancer and has distinct expression patterns and diagnostic biomarker significance in cancer. Additionally, high levels of CCL5 were associated with a stronger immunotherapeutic response and better prognosis after immunotherapy. The study suggests that CCL5 has the potential to be used as an immunotherapeutic response biomarker and prognostic indicator in cancer treatment. [Extracted from the article]

A recent study conducted at the University of Cincinnati investigated the effects of tranexamic acid (TXA) administration on inflammation and phosphorylated tau (p-tau) levels in the hippocampus after traumatic brain injury (TBI). Male mice were divided into six groups and subjected to TBI with varying timings of TXA administration. The study found that neither early nor delayed administration of TXA had a significant impact on systemic or cerebral cytokine levels following TBI. Further research is needed to assess blood-brain barrier integrity and neurobehavioral recovery after TXA administration post-TBI. [Extracted from the article]

A recent report from the University of Minnesota discusses the findings of a study on tissue engineering and bone regeneration. The researchers focused on the effects of a high-fat/high-sugar diet on bone healing and the potential anti-inflammatory properties of HDAC inhibitors. The study found that mice with HDAC3 deficiency showed enhanced intramembranous bone healing and reduced periosteal reaction tissue when fed a high-fat/high-sugar diet. The researchers also observed increased production of the chemokine CCL2 in HDAC3-deficient mice, which may contribute to the improved bone healing. This research provides insights into the potential role of HDAC3 in bone regeneration and the impact of diet-induced obesity on bone healing. [Extracted from the article]

A patent has been issued to Accelerated Biosciences Corp. for precursory regulatory cytotrophoblast cells and their potential uses in stem cell therapies. The patent describes an isolated population of cells that express various proteins and receptors, including human chorionic gonadotropin, insulin, heat shock proteins, and cytokines. These cells may have applications in treating a variety of diseases and conditions. The patent also includes claims for pharmaceutical compositions containing these cells and an acceptable carrier. Further research and development are needed to explore the potential of these cells in medical treatments. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Guangxi Medical University in China explored the role of C-C chemokine receptor type 2-positive (CCR2+) macrophages in rheumatic heart disease (RHD). RHD is an autoimmune disease caused by recurrent infections of Group A streptococcus (GAS) that leads to inflammation and fibrosis of heart valves. The study found that CCR2+ macrophages are involved in the valvular remodeling process of RHD. Inhibiting the CCL2/CCR2 signaling pathway may be a potential therapeutic strategy to reduce valve fibrosis in RHD. [Extracted from the article]

A recent study conducted by researchers at the First Affiliated Hospital of Anhui University of Chinese Medicine explored the mechanism of Taohong Siwu Decoction (THSWD) for the treatment of ischemic stroke. THSWD is a traditional Chinese herbal prescription that has shown effectiveness in treating ischemic stroke. The study used bioinformatics analysis, in vitro and in vivo experiments to investigate the mechanism of action of THSWD. The results indicated that THSWD may play a protective role in ischemic stroke by inhibiting the CCL2/CCR2 axis, reducing macrophage infiltration, promoting the polarization of M2 macrophages, and protecting the blood-brain barrier. [Extracted from the article]

A study conducted at the University of Leipzig in Germany explores the role of glutaminyl cyclase (QC) in brain ischemia, a condition characterized by reduced blood flow to the brain. The researchers found that QC expression increased in the infarct area of mice after ischemia, suggesting its involvement in inflammatory processes in the stroke-affected brain. The study also observed an increase in the chemokine CCL2, which is known to contribute to inflammation in neurodegenerative conditions. These findings provide insights into the molecular and cellular responses to brain ischemia and highlight the potential role of QC in inflammatory pathways. [Extracted from the article]

A recent study published in the International Journal of Molecular Sciences explores the role of Toll-like receptor 7 (TLR7) in the immune response induced by the rabies virus (RABV). The study found that different strains of RABV significantly increased the production of chemokines CCL2 and CXCL10, as well as the cytokine IL-6. Blocking TLR7 reduced the expression of these immune factors. Additionally, the study demonstrated that RABV-induced expression of CCL2, CXCL10, and IL-6 involves the Myd88 and NF-kB signaling pathways via the TLR7 signal. This research provides valuable insights into the mechanisms of the immune response to RABV infection. [Extracted from the article]

Researchers at Fudan University in Shanghai, China have conducted a study on oxaliplatin therapy and its role in hepatocellular carcinoma (HCC). The study found that a positive feedback loop involving DDR2 and STAT3 contributes to immune evasion and resistance to oxaliplatin in HCC. This loop leads to the upregulation of PD-L1 and the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Inhibiting the DDR2/STAT3 pathway may be a potential therapeutic strategy to overcome immune escape and chemoresistance in HCC. [Extracted from the article]

The patent application titled "Systems And Methods For Driving Neural Activity To Control Brain Signaling And Gene Expression" proposes methods for controlling brain activity by delivering a non-invasive stimulus to the brain. This stimulus, such as a sensory flicker, can be delivered for less than one hour and has the potential to treat neurological diseases, injuries, conditions, and infections, as well as promote healthy aging. The methods aim to induce neural activity, modulate the expression of cellular mediators, and invoke an immunomodulatory response. The patent application provides a list of soluble mediators and neurological conditions that can be targeted using these methods. For more information, please refer to the full patent application. [Extracted from the article]

A recent study conducted by researchers at Newcastle University examined the expression of the chemokine C-C motif ligand 2 (CCL2) and its receptor C-C motif chemokine receptor 2 (CCR2) in locally advanced prostate cancer. The study analyzed data from the TROG 03.04 RADAR clinical trial and found that while CCR2 protein expression was associated with prostate-specific antigen serum concentration, neither CCL2 nor CCR2 expression could predict prostate cancer progression or other clinicopathological parameters. Additionally, circulating CCL2 was not a significant predictor of disease progression or patient outcome. The study concludes that although CCL2 and CCR2 are expressed in prostate cancer, they do not have clinical prognostic value in locally advanced prostate cancer. [Extracted from the article]

A recent study conducted at the University of North Carolina in Chapel Hill explored the role of a neurosteroid called [3a,5a]3-hydroxypregnan-20-one (3 alpha,5 alpha-THP) in inhibiting the overexpression of the chemokine monocyte chemoattractant protein-1 (MCP-1) in the brains of alcohol-preferring rats. The researchers focused on neurons, microglia, and astrocytes in the nucleus accumbens (NAc) and central amygdala (CeA) regions of the brain. They found that 3 alpha,5 alpha-THP reduced MCP-1 expression in neurons and decreased the proliferation of microglia in the rats. These findings contribute to our understanding of the potential mechanisms involved in regulating ethanol consumption. [Extracted from the article]

A recent study conducted by Charite - University Medicine Berlin examined the characteristics of pruritus (itching) in primary cutaneous T-cell lymphoma (CTCL) patients. The researchers found that pruritus was prevalent and severe in CTCL patients, leading to significant impairment in quality of life, sleep, and psychological distress. Elevated levels of certain mediators, such as IL-31 and tryptase, were found in CTCL patients with pruritus, suggesting that these could be potential therapeutic targets for managing itching in CTCL patients. The study highlights the need for appropriate therapeutic management of pruritus in CTCL patients. [Extracted from the article]

A recent study conducted at Kaohsiung Veterans General Hospital in Taiwan explored the effects of interleukin-10 (IL-10) on insulin resistance and liver gluconeogenesis in diabetic mice. The researchers found that IL-10 treatment reduced inflammation in the adipose tissue of diabetic mice and improved glucose tolerance. Additionally, IL-10 treatment increased the expression of regulatory T cells (Tregs) and decreased the activity of DPP4, a protein associated with insulin resistance. These findings suggest that IL-10-treated adipose stromal vascular cells could be a potential therapeutic strategy for diabetes mellitus. [Extracted from the article]

A patent application titled "Cannabidiol For Treating Neurodegenerative Diseases" has been published online by the US Patent and Trademark Office. The patent application, filed by Augusta University Research Institute Inc., describes the use of cannabidiol (CBD) to treat neurodegenerative diseases such as Alzheimer's disease. The inventors propose that CBD can improve cognitive function and reduce inflammation in the brain, potentially providing a therapeutic benefit for these diseases. The patent application also mentions the financial burden and lack of effective drugs for treating neurodegenerative diseases. [Extracted from the article]

A recent study conducted by researchers at the University of Kansas Medical Center explores the role of C-C chemokine ligand 2 (CCL2) signaling in skeletal muscle wasting (SMW) in breast cancer patients. SMW affects approximately 25% of breast cancer patients and can have negative impacts on mobility, drug tolerance, and survival. The study found that elevated levels of CCL2 in breast cancer patients may contribute to SMW through various signaling pathways. The researchers suggest that understanding these mechanisms could lead to the development of new strategies to alleviate SMW and improve the lives of breast cancer patients. [Extracted from the article]

Researchers from Justus-Liebig-University have conducted a study on CC chemokines and their role in bronchopulmonary dysplasia (BPD), a condition caused by oxygen toxicity in premature infants. The study found that the inflammatory response in the immature lung, characterized by the release of pro-inflammatory cytokines and the influx of innate immune cells, is a critical step in the development of BPD. The researchers identified CCL-2, a chemokine involved in macrophage recruitment, as a potential target for therapy. By blocking CCL-2 function, the researchers were able to reduce the pulmonary inflammatory response and protect the immature lung from hyperoxic injury. This study provides valuable insights into the pathogenesis of BPD and offers a novel approach for its prevention and treatment. [Extracted from the article]

A recent study conducted at Hamadan University of Medical Sciences in Iran explored the role of glia maturation factor beta (GMF beta) in toxoplasmosis, a parasitic infection caused by Toxoplasma gondii. The researchers found that GMF beta expression increased significantly in neuroblastoma cells infected with T. gondii, suggesting that GMF beta upregulation may be an indicator of nerve cell destruction. This study provides new insights into the neuro-impairment prediction factors associated with toxoplasmosis. Further research is needed to fully understand the implications of GMF beta in this context. [Extracted from the article]

A new report from the Medical University of Silesia in Poland provides fresh data on atherosclerosis, a leading cause of cardiovascular disease. The study focused on the effects of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on diabetic patients with atherosclerotic plaque. The researchers found that GLP-1RA treatment resulted in improvements in various health parameters, including glycemic control and blood pressure. Additionally, the treatment led to favorable changes in serum molecule levels associated with monocyte recruitment to the endothelium. Further research is needed to fully understand the mechanisms and clinical implications of these findings. [Extracted from the article]

A recent study conducted at the University Hospital Erlangen in Germany has examined the expression of the chemokine CC motif ligand 5 (CCL5) in muscle-invasive bladder cancer patients. The researchers found that positive CCL5 staining in tumor cells was associated with shorter disease-specific survival, while negative CCL5 staining in immune cells was associated with shorter overall survival, disease-specific survival, and recurrence-free survival. The study suggests that CCL5 expression could serve as a prognostic and predictive marker for muscle-invasive bladder cancer patients. The research was funded by various foundations and organizations. [Extracted from the article]

A recent study conducted at Soochow University in Suzhou, China, has shed light on the mechanisms underlying bone metastasis in lung adenocarcinoma (LUAD). The researchers established an in vivo model of LUAD bone metastasis and found that bone metastatic (BoM) cells exhibited greater stemness and plasticity compared to lung metastatic (LuM) cells. They also discovered a CD74-ROS1 fusion mutation in BoM cells, which led to the secretion of the C-C motif chemokine ligand 5 (CCL5) protein and the recruitment of macrophages. These macrophages then facilitated the invasion of LUAD cells through the TGF-beta/SMAD2/3 signaling pathway. The study suggests that targeting the CD74-ROS1/CCL5 axis could be a promising therapeutic strategy for LUAD bone metastasis. [Extracted from the article]

A study conducted at Capital Medical University in Beijing, China, explored the association between plasma levels of monocyte chemoattractant protein-1 (MCP-1) and 28-day mortality in elderly patients with sepsis. The study included 136 patients diagnosed with sepsis between October 2020 and October 2021. The findings revealed that higher levels of MCP-1 were significantly associated with increased 28-day mortality in patients with sepsis. The study suggests that MCP-1 could serve as a potential biomarker for predicting outcomes in sepsis patients. [Extracted from the article]

A patent application titled "Nucleic Acid Vectors And Methods Of Use" has been made available online, proposing a gene therapy approach for treating cancer. The application describes nucleic acid vectors that carry immunomodulatory genes to modulate the tumor microenvironment. These vectors can be administered with an electric field to enhance their delivery into target cells. The invention also includes pharmaceutical compositions and methods for treating cancer using these vectors. This patent application presents a potential advancement in cancer treatment by utilizing gene therapy to improve outcomes. [Extracted from the article]

A study conducted by researchers at Eskisehir Osmangazi Universitesi provides new insights into lung cancer. The study found that lung cancer patients had significantly higher levels of inducible nitric oxide synthase (iNOS), monocyte chemoattractant protein-1 (MCP-1), and cyclooxygenase-2 (COX2) in their serum compared to healthy individuals. These findings suggest that inflammation may play a role in the development and progression of lung cancer. The researchers believe that these findings could contribute to early diagnosis and the development of new treatments for lung cancer. [Extracted from the article]

A patent has been issued for beta-catenin inhibitors in cancer immunotherapy by the University of Chicago. The patent describes compositions and methods for treating cancer by inhibiting beta-catenin or the Wnt/beta-catenin signaling pathway. These inhibitors can prevent or reverse the evasion of immune response by cancers. The methods involve administering the inhibitors to subjects with solid tumor cancer, particularly melanoma, who have tumors that exclude T-cell infiltration. Additional therapeutic agents, such as chemotherapeutic or immunotherapeutic agents, can be co-administered. The patent also discusses testing for specific biomarkers and the use of dendritic-cell therapy or T-cell therapy in combination with the inhibitors. [Extracted from the article]

A recent study conducted in Hebei, China, examined the expression of certain markers in patients with vitiligo, a chronic depigmentation of the skin. The researchers compared 30 healthy individuals to 60 vitiligo patients, including those with active and stable disease. They found that the serum levels of monocyte chemoattractant protein-1 (MCP-1), chemokine (C-C motif) ligand 3 (CCL3), interleukin-6 (IL-6), and IL-17 were significantly higher in vitiligo patients compared to healthy controls. Additionally, IL-17 levels were higher in patients with active vitiligo compared to those with stable vitiligo. The study suggests that IL-17 could be used as a marker for disease activity and guide clinical treatment. [Extracted from the article]

A recent study conducted at Tongji University in Shanghai, China, explored the relationship between chronic pelvic pain (CPP) and changes in the central nervous system. The researchers established a rat model of CPP and observed higher levels of chemokine ligand 2 (CCL2) in the serum exosomes, pelvic vascular endothelial cells, and cerebrospinal fluid of the CPP group compared to the control group. They also found that CCL2 can activate the Notch2 signaling pathway, suggesting its role in the central sensitization of chronic pelvic pain. This research provides valuable insights into the understanding and potential treatment of CPP. [Extracted from the article]

A recent study conducted by researchers at Huazhong University of Science and Technology in Wuhan, China, has provided new information about immune-mediated necrotizing myopathy (IMNM). The study found that monocyte chemoattractant protein-1 (MCP-1) plays a key role in regulating the infiltration of monocytes and macrophages into injured muscle tissues. The researchers also discovered that interleukin-6 (IL-6) signaling is involved in the induction of MCP-1 expression in human myoblasts. These findings suggest that IL-6 trans-signaling may contribute to the immunopathogenesis of IMNM by increasing inflammation through the regulation of MCP-1 expression. [Extracted from the article]

A study conducted by researchers from Henan University of Chinese Medicine used single-cell RNA sequencing technology to analyze the cellular communication landscape of coronary atherosclerosis (CA). The study identified 11 cell subsets in CA lesions, with smooth muscle cells being the dominant cell subgroup. The researchers found that smooth muscle cells have extensive communication networks with other cells, particularly endothelial cells, macrophages, and monocytes. The study also identified key genes involved in the communication network, such as CCL2 and ITGB2. The findings were validated through animal experiments. [Extracted from the article]

A recent study conducted in Baghdad, Iraq, examined the levels of a cytokine called CCL3 in individuals with newly diagnosed chronic lymphocytic leukemia (CLL). The study found that patients with CLL had higher levels of CCL3 compared to healthy individuals. There was a strong correlation between CCL3 levels and certain hematological and clinical parameters, such as white blood cell count and Binet stage. The researchers concluded that measuring CCL3 plasma levels could be a useful tool for risk assessment and follow-up in CLL patients. [Extracted from the article]

A recent study conducted by researchers at the Icahn School of Medicine at Mount Sinai explored the significance and pathophysiology of enlarged perivascular spaces in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). The study found that increased volumes of enlarged perivascular spaces were associated with white matter injury, cognitive decline, and inflammation in individuals with CADASIL. Additionally, certain plasma proteins were found to be related to leukocyte migration and inflammation, while others were related to lipid metabolism. The findings suggest that enlarged perivascular spaces may contribute to chronic brain dysfunction and degeneration in CADASIL. [Extracted from the article]

A recent study conducted at Zhongshan Hospital in Shanghai, China, has explored the role of signaling lymphocytic activation molecule (SLAM) family members in hepatocellular carcinoma (HCC) and their potential impact on immunotherapy response. The researchers found that SLAMF7, a specific SLAM receptor, was upregulated in HCC patients who responded to immunotherapy. They also discovered that SLAMF7 played a role in regulating macrophage function and suppressing the expression of chemokine CCL2, which affects macrophage migration and polarization. The study suggests that targeting CCL2 signaling to induce macrophage repolarization in HCC with low SLAMF7 expression could enhance the efficacy of immunotherapy. [Extracted from the article]